This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (168)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

Causal or Casual?

William G. Christen, ScD; Umed A. Ajani, MBBS; Robert J. Glynn, ScD; Charles H. Hennekens, MD

Arch Intern Med. 2000;160:422-434.

Background  Accumulating data from epidemiological studies suggest that individuals with elevated blood levels of homocysteine have increased risks of cardiovascular disease. We reviewed the currently available evidence of an association between homocysteine and cardiovascular disease and examined whether the strength of the evidence varies according to study design.

Methods  We used a computerized MEDLINE literature search, 1966 through September 1998, to identify all epidemiological studies that examined the relationship of homocysteine level with risks of coronary heart or cerebrovascular disease. Two measures of plasma homocysteine level and its association with risk of cardiovascular disease were extracted: mean homocysteine level in cases and controls, and relative risk of cardiovascular disease for elevated homocysteine level.

Results  A total of 43 studies were reviewed. Most cross-sectional and case-control studies indicated higher mean homocysteine levels (either fasting or after methionine load) and/or a greater frequency of elevated homocysteine level in persons with cardiovascular disease as compared with persons without cardiovascular disease. Results of most prospective studies, however, indicated smaller or no association. The few prospective studies that reported a positive association between homocysteine level and risks of cardiovascular disease included patients with preexisting vascular disease.

Conclusions  In contrast to cross-sectional and case-control studies, results of prospective studies indicated less or no predictive ability for plasma homocysteine in cardiovascular disease. Instead, elevated homocysteine level may be an acute-phase reactant that is predominantly a marker of atherogenesis, or a consequence of other factors more closely linked to risks of cardiovascular disease. Randomized trials are necessary to test reliably whether lowering homocysteine levels will decrease risks of cardiovascular disease.

From the Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (Drs Christen, Ajani, and Glynn), and Department of Biostatistics, Harvard School of Public Health (Dr Glynn), Boston, Mass. Dr Hennekens is now Visiting Professor of Medicine, and Epidemiology and Public Health, University of Miami School of Medicine, Miami, Fla.

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(4):555-556.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Negative outcome studies in end-stage renal disease: how dark are the storm clouds?
Covic et al.
Nephrol Dial Transplant 2008;23:56-61.
FULL TEXT  

Homocysteine, vitamins, and vascular disease prevention
McCully
Am. J. Clin. Nutr. 2007;86:1563S-1568S.
ABSTRACT | FULL TEXT  

TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease
Carlson et al.
J. Lipid Res. 2006;47:1014-1024.
ABSTRACT | FULL TEXT  

Orally Administered Betaine Has an Acute and Dose-Dependent Effect on Serum Betaine and Plasma Homocysteine Concentrations in Healthy Humans
Schwab et al.
J. Nutr. 2006;136:34-38.
ABSTRACT | FULL TEXT  

Downstream effects on human low density lipoprotein of homocysteine exported from endothelial cells in an in vitro system
Nakano et al.
J. Lipid Res. 2005;46:484-493.
ABSTRACT | FULL TEXT  

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Ability of Inflammatory Markers to Predict Disease in Asymptomatic Patients: A Background Paper
Wilson
Circulation 2004;110:e568-e571.
ABSTRACT | FULL TEXT  

Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Martinez-Berriotxoa et al.
Lupus 2004;13:927-933.
ABSTRACT  

Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study
Frederiksen et al.
Blood 2004;104:3046-3051.
ABSTRACT | FULL TEXT  

Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia
Quadri et al.
Am. J. Clin. Nutr. 2004;80:114-122.
ABSTRACT | FULL TEXT  

Homocysteine, a Risk Factor for Carotid Atherosclerosis, Is Not a Risk Factor for Early Recurrent Carotid Stenosis Following Carotid Endarterectomy
Samson et al.
VASC ENDOVASCULAR SURG 2004;38:345-348.
ABSTRACT  

Glycine rectifies vascular dysfunction induced by dietary protein imbalance during pregnancy
Brawley et al.
J. Physiol. 2004;554:497-504.
ABSTRACT | FULL TEXT  

Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion
Refsum et al.
Clin. Chem. 2004;50:3-32.
ABSTRACT | FULL TEXT  

Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking: The Framingham Heart Study
Sundstrom et al.
Hypertension 2003;42:1100-1105.
ABSTRACT | FULL TEXT  

Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
Hackam and Anand
JAMA 2003;290:932-940.
ABSTRACT | FULL TEXT  

Risk of Myocardial Infarction in Relation to Plasma Levels of Homocysteine and Inflammation-Sensitive Proteins: A Long-Term Nested Case-Control Study
Lind et al.
ANGIOLOGY 2003;54:401-410.
ABSTRACT  

Secondary prevention with folic acid: effects on clinical outcomes
Liem et al.
J Am Coll Cardiol 2003;41:2105-2113.
ABSTRACT | FULL TEXT  

Folic Acid Supplements and Fortification Affect the Risk for Neural Tube Defects, Vascular Disease and Cancer: Evolving Science,
Bailey et al.
J. Nutr. 2003;133:1961S-1968.
ABSTRACT | FULL TEXT  

Homocysteine and Cerebral Infarction in Finnish Male Smokers
Fallon et al.
Stroke 2003;34:1359-1363.
ABSTRACT | FULL TEXT  

Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study
Venn et al.
Am. J. Clin. Nutr. 2003;77:658-662.
ABSTRACT | FULL TEXT  

Vitamin B-12 metabolism in HIV-infected patients in the age of highly active antiretroviral therapy: role of homocysteine in assessing vitamin B-12 status
Remacha et al.
Am. J. Clin. Nutr. 2003;77:420-424.
ABSTRACT | FULL TEXT  

Plasma Vitamin B6 Vitamers before and after Oral Vitamin B6 Treatment: A Randomized Placebo-controlled Study
Bor et al.
Clin. Chem. 2003;49:155-161.
ABSTRACT | FULL TEXT  

Update on Cobalamin, Folate, and Homocysteine
Carmel et al.
ASH Education Book 2003;2003:62-81.
ABSTRACT | FULL TEXT  

Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease
De Bree et al.
Pharmacol. Rev. 2002;54:599-618.
ABSTRACT | FULL TEXT  

Coronary atherogenic risk factors in women
Stangl et al.
Eur Heart J 2002;23:1738-1752.
FULL TEXT  

Dietary counseling to increase natural folate intake: a randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine
Venn et al.
Am. J. Clin. Nutr. 2002;76:758-765.
ABSTRACT | FULL TEXT  

Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia
Weiss et al.
Vasc Med 2002;7:227-239.
ABSTRACT  

Hyperhomocyst(e)inemia and Risk of Ischemic Stroke Among Young Asian Adults
Tan et al.
Stroke 2002;33:1956-1962.
ABSTRACT | FULL TEXT  

Plasma Total Homocysteine and Hospitalizations for Cardiovascular Disease: The Hordaland Homocysteine Study
Nurk et al.
Arch Intern Med 2002;162:1374-1381.
ABSTRACT | FULL TEXT  

Riboflavin Is a Determinant of Total Homocysteine Plasma Concentrations in End-Stage Renal Disease Patients
Skoupy et al.
J. Am. Soc. Nephrol. 2002;13:1331-1337.
ABSTRACT | FULL TEXT  

Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies
Ford et al.
Int J Epidemiol 2002;31:59-70.
ABSTRACT | FULL TEXT  

Changes in Plasma Homocyst(e)ine in the Acute Phase After Stroke
Howard et al.
Stroke 2002;33:473-478.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Homocysteine-Lowering Therapy to Prevent Coronary Heart Disease
Bostom et al.
JAMA 2002;287:190-192.
FULL TEXT  

Folates and Cardiovascular Disease
Verhaar et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:6-13.
ABSTRACT | FULL TEXT  

Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension
Virdis et al.
J Am Coll Cardiol 2001;38:1106-1115.
ABSTRACT | FULL TEXT  

Dietary Supplementation With Methionine and Homocysteine Promotes Early Atherosclerosis but Not Plaque Rupture in ApoE-Deficient Mice
Zhou et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1470-1476.
ABSTRACT | FULL TEXT  

Lifestyle Factors and Plasma Homocysteine Concentrations in a General Population Sample
Bree et al.
Am J Epidemiol 2001;154:150-154.
ABSTRACT | FULL TEXT  

Hyperhomocystinemia: A Risk Factor or a Consequence of Coronary Heart Disease?
Knekt et al.
Arch Intern Med 2001;161:1589-1594.
ABSTRACT | FULL TEXT  

Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study
Vollset et al.
Am. J. Clin. Nutr. 2001;74:130-136.
ABSTRACT | FULL TEXT  

Response to Chan et al.: Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes
Buysschaert and Hermans
Diabetes Care 2001;24:1124-1125.
FULL TEXT  

Homocysteine and ischaemic stroke in men: the Caerphilly study
Fallon et al.
J. Epidemiol. Community Health 2001;55:91-96.
ABSTRACT | FULL TEXT  

Role of nested case-control studies in the difficult quest for new coronary risk factors
CREA
Heart 2001;85:125-126.
FULL TEXT  

Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up
Fallon et al.
Heart 2001;85:153-158.
ABSTRACT | FULL TEXT  

Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association
Goldstein et al.
Circulation 2001;103:163-182.
FULL TEXT  

Primary Prevention of Ischemic Stroke : A Statement for Healthcare Professionals From the Stroke Council of the American Heart Association
Goldstein et al.
Stroke 2001;32:280-299.
FULL TEXT  

Potential Clinical and Economic Effects of Homocyst(e)ine Lowering
Nallamothu et al.
Arch Intern Med 2000;160:3406-3412.
ABSTRACT | FULL TEXT  

Clinical and research challenges in risk factors for cardiovascular diseases
Hennekens
Eur Heart J 2000;21:1917-1921.
 

Serum Total Homocysteine Concentration Is Related to Self-Reported Heart Attack or Stroke History among Men and Women in the NHANES III
Morris et al.
J. Nutr. 2000;130:3073-3076.
ABSTRACT | FULL TEXT  

Homocysteine in Cardiovascular Disease: Causal or Casual?
JWatch Neurology 2000;2000:5-5.
FULL TEXT  

Fortification of Foods with Folic Acid -- How Much is Enough?
Mills
NEJM 2000;342:1442-1445.
FULL TEXT  

Endothelial Dysfunction and Elevation of S-Adenosylhomocysteine in Cystathionine {beta}-Synthase-Deficient Mice
Dayal et al.
Circ. Res. 2001;88:1203-1209.
ABSTRACT | FULL TEXT